By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


LFB Biotechnologies 

3, avenue des Tropiques

Les Ulis  Cedex  91958  France
Phone: Fax:


Company News
TG Therapeutics, Inc. (MHA) Nabs $25 Million; Completes Licensing Agreement With LFB Biotechnologies for the Development of Ublituximab 3/2/2012 7:38:49 AM
Acquisition of GTC Biotherapeutics (GTCB) by LFB Biotechnologies Completed 12/6/2010 11:17:16 AM
Thallion Pharmaceuticals Inc. and LFB Biotechnologies Initiate Phase II SHIGATEC Trial 11/29/2010 9:51:57 AM
French Biotech LFB Biotechnologies to Buy GTC Biotherapeutics (GTCB); GTC Agrees to go Private for $.30 Per Share 11/8/2010 8:03:05 AM
LFB Biotechnologies Offers to Take GTC Biotherapeutics (GTCB) Private for $.28 Per Share for Total of $17 Million 10/19/2010 7:13:01 AM
BAC B.V. Affinity Ligand Licensed for Clinical and Commercial Scale-up of LFB Biotechnologies' Recombinant Factor VIIa 4/13/2010 10:24:24 AM
GTC Biotherapeutics (GTCB) Enters into Agreement to Receive $7 Million in Financing from LFB Biotechnologies 2/22/2010 6:26:41 AM
Thallion Pharmaceuticals Inc. and LFB Biotechnologies Sign Definitive Agreement to Develop and Commercialize Treatment for E. Coli (STEC) Infection; Thallion Eligible to Receive up to 95 Million Euros 2/16/2010 8:51:25 AM
Thallion Pharmaceuticals Inc. Announces Letter of Intent With LFB Biotechnologies to Develop and Commercialize Shigamabs(R) 12/18/2009 10:14:24 AM
LFB Biotechnologies's Recombinant Anti-CD20 Monoclonal Antibody is Granted Orphan Drug Status in Europe for Chronic Lymphocytic Leukemia 11/25/2009 9:05:32 AM